DeepValueStocks
Posted - 9 minutes ago
$MTNB Near-term TA looking lovely: BREAKOUT TRADE: Watch for possible breakout above 0.299 Target: 0.361, 24.5% Stop: 0.267 Loss: 7.9% P/L ratio: 3.1 : 1 - Excellent
DeepValueStocks
Posted - 13 minutes ago
$MTNB If a multi-regional partnership deal for MAT 2203 and our *OTHER.....(*cancer, inflammation, colitis, psoriasis)LNC assets are around the corner (2Q24), shouldn't analysts bump up their existing PTs ??? And if they don't, can we all assume that "silent upgrades" were likely made ?
Navtalk
Posted - 1 hour ago
$MTNB if partnership happens and from them if we get funding for trial 3 . Will stock price goes up?
DOC1977
Posted - 1 hour ago
$MTNB overall things r looking better , just need the cash and I’m sure with the positive data we have in different areas I think a partnership is imminent…….
levystrauss
Posted - 2 hours ago
$MTNB I don't know what to think, but if the science is as good as it seems, they should make an OFFERING for $1 and see if it works. Maybe they could buy 10 million shares themselves with their own money, producing a boomerang effect on the future price....but this is a financial fantasy...:-))))
tdohm22
Posted - 4 hours ago
$MTNB
valueforme
Posted - 10 hours ago
$MTNB If we can dream of a Big Pharma at MAT2203 global anti-infectives partner, what are the options? Top-5 is below. Let's review: - Merck? Nothing in the anti-infectives pipeline for years, do they still care? - Gilead? Challenging history of previous relationships, AmBisome market share (why to buy something to compete with your other product) - GSK? Maybe, they are doing interesting deals recently, e.g. Spero - Pfizer? No, they got rid of another antifungal asset recently. - Novartis? Not Novartis, but Sandoz, their generics spin-off. Maybe, they bought Mycamine rights a year ago. GSK or Sandoz would be f*cking awesome. But big boys are not quick to sign deals with.
tdohm22
Posted - 10 hours ago
$MTNB
bagholderluck
Posted - 11 hours ago
$MTNB These mat2203 offers must be amazing for J and team not to accept them. Wait, that makes no sense.
shakeslear86
Posted - 11 hours ago
$MTNB I am impressed with several outcomes. (1) The price in the after market has held up. (2) The team is not looking for BARDA $ but focussed on one or more partners with a strong world wide sales force. Do this in Q2. And they will likely be focussing on LNC/chemo as their second LNC/generic product. Sounds good to me with low risk and huge market. I am hoping a 2203 partner is a candidate for doing LNC/docetaxel also. Setting up LNC manufacturing for 2203 should help set up for other payloads.
febiyanr
Posted - 11 hours ago
$MTNB when is the next catalyst? I was expecting something big from the ER haha.
valueforme
Posted - 12 hours ago
$MTNB The funny thing is that they never filed Feb 2022 Rutgers Second Amended and Restated Exclusive License Agreement with SEC, so we don't know what is a deadline for Rutgers license to terminate for non commencing commercial sales. Original agreement had 29th of January, 2015 as a restatement date and this termination close: "Nine (9) years have elapsed from the RESTATEMENT DATE, LICENSEE, an AFFILIATE or a sublicensee has not commenced commercial sales of at least one LICENSED PRODUCT, and LICENSOR has given LICENSEE ninety (90) days’ notice of intent to terminate."
tdohm22
Posted - 12 hours ago
$MTNB I think I’ve developed a thyroid condition from these guys….I do not feel well
DeepValueStocks
Posted - 12 hours ago
$MTNB In summary, a global licensing deal will happen but it's simply a question of "when". Big pharma pulls the trigger when big pharma decides to pull the trigger. 2203 is ready to go and the LNC factory is busy looking to expand into cancer, inflammation, colitis and psoriasis. What's not to like ?
Mario081
Posted - 12 hours ago
$MTNB The prerequisites are good, but not what we wanted to hear. I'm hoping for a short sell-off due to the failure to deliver the promised results in Q 1 so that we can buy again, and then maybe we'll see each other again at the end of May with new information, until then there will be radio silence again.
RedOneBNTX
Posted - 12 hours ago
$MTNB I liked the discussion about the cost savings of MAT2203 for hospitals and insurance, which will increase the price of the pills.
tdohm22
Posted - 13 hours ago
$MTNB 4 more years guys….then we may get back over $1.00! Let the good times role baby. Down payment on a Toyota here I come!!
RoyBaschMD
Posted - 13 hours ago
$MTNB be patient and everything will be good at the end 👍🏻
Terps99
Posted - 13 hours ago
$MTNB did they say anything about r/s or offering. Anything like that?
Just got out of work
omega42
Posted - 13 hours ago
$MTNB two words to summarize "cautiously optimistic" and currently I want to see a partner irrespective of timeline it take to enroll and get it to market. Secondly, with 65 sites across different continents, it should be rather quick process to enroll patients....less than 4 per each site and why does it need to take 2 years to enroll?
epster
Posted - 13 hours ago
$MTNB Telephone music was "set fire to the rain" by Adele. How fitting for the passionate loyal MTNB investors. lol. Gemini: The song is about a passionate and stormy relationship. Lines like "Cause there's a side to you / That I never knew, never knew" and "All the things you'd say / They were never true, never true" depict a love that's falling apart. The rain symbolizes tears and sadness, and "setting fire to the rain" becomes a metaphor for the intensity of the emotions involved.
mdrins00
Posted - 13 hours ago
$MTNB so think about this for a minute...we're FOUR years away from a potential MAT2203 launch. you know both JJ and TM just hated uttering "Twenty.....Twenty Eight". reality check: how long do you think it will take to possibly, maybe, launch an LNC formulation of ANYTHING oncology or inflammation related? if you have toddlers at home, today, they will be in highschool by the time that day comes to pass. and given the rapidly evolving delivery landscape, does LNC have that long?
DeepValueStocks
Posted - 13 hours ago
$MTNB Jerry's hesitancy to talk with bravado is a good sign that he learned his lesson from BNTX and is listening to his advisors. Said something earlier that we should hear about more milestones in 2Q24 (Deal announcement ?)
mdrins00
Posted - 13 hours ago
$MTNB 4 yrs until commercial launch. that is the price for all this dicking around.
valueforme
Posted - 13 hours ago
$MTNB Potential approval in 2028, what if someone told you that in Sept 2021 when EnAct Cohort 2 data was out?
tdohm22
Posted - 13 hours ago
$MTNB c’mon…ask him the only question that matters…why does the market never validate our science, but does so with every single other biotech company? Especially, with the illiquidity of the pre-market when our news is often delivered and the pedigree of our BOD.
DeepValueStocks
Posted - 13 hours ago
$MTNB They are going the partnership route asap to not only monetize 2203 but also their other assets in cancer & inflammation, and they said they are looking for a multi-regional deal.
tdohm22
Posted - 13 hours ago
$MTNB hey BTIG! While we have you here…where is our price target reiteration. I’ll help you out….should be $6.00 per share
markmorrow
Posted - 13 hours ago
$MTNB Extended the cash from into the 3rd Q to the end of 3rd q.